Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825004 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL9850706 | 0.68 | ALDH1A1 (0.36) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL7606328 | 0.67 | KDM4E (0.33) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL5635994 | 0.67 | — | — | |
| SCHEMBL9730822 | 0.66 | ALOX15 (0.36) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL6787340 | 0.66 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL31746097 | 0.66 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EGAAMAPTHPGD | |
| SCHEMBL226035 | 0.66 | GAA (0.41) | GAAMAPTCYP1A2 | |
| SCHEMBL5866059 | 0.63 | — | — | |
| SCHEMBL3579949 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0227982-A1 | 1-H-Pyrido[3,2-b][1,4]thiazines | BAYER AG (DE) | 1987-07-08 | — | — | EP | claimed |
| US-11786575-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220211802-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2022-07-07 | — | — | US | disclosed |
| US-11331369-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3717478-A1 | ENDOPARASITIC DEPSIPEPTIDES | Zoetis Services LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200282016-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2020-09-10 | — | — | US | disclosed |
| WO-2013188856-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-5232930-A | Antiinflammatory antiallergen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-03 | — | — | US | disclosed |
| EP-0500205-A1 | Benzodioxole derivatives | ZENECA LIMITED (GB) | 1992-08-26 | — | — | EP | disclosed |
| US-4784997-A | INHIBITORS OF LIPOXYGENASE, ANTIINFLAMMMATORY AGENTS, ANTIALLERGENS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0227982-A1 | 1-H-Pyrido[3,2-b][1,4]thiazines | BAYER AG (DE) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786575-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | SMN1; SMN2 3040/4885KDM4E 3941/4885GAA 553/4885 |
| US-20200282016-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | SMN1; SMN2 3040/4885KDM4E 3941/4885GAA 553/4885 |
| US-20220211802-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | SMN1; SMN2 3040/4885KDM4E 3941/4885GAA 553/4885 |
| US-11331369-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | SMN1; SMN2 3040/4885KDM4E 3941/4885GAA 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.